SAP Partners with Gurobi to Enhance and Expand Optimization Capabilities Across its Enterprise Application Software Suite
Gurobi Optimization, LLC today announced that it has been selected by SAP SE (NYSE: SAP) as the premier, enterprise-wide supplier for mathematical optimization technology, and has entered into a long-term strategic partnership with SAP to enhance and expand the use of mathematical optimization across SAP’s enterprise application software suite. As a result of the partnership, SAP and Gurobi will be able to more effectively collaborate on innovations that will improve the utilization of mathematical optimization within SAP’s software.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005232/en/
“Mathematical optimization continues to be an important cornerstone along with our accelerated investment into intelligent algorithms such as AI/ML,” said SAP Senior Vice President of Development for Digital Supply Chain Franz Hero. “Combining these approaches will offer our customers a differentiated set of advanced tools for better automation and decision support.”
The Gurobi Optimizer has been a key component of SAP’s supply chain management solutions since 2015.
Under the 10-year Enterprise Agreement signed by SAP and Gurobi:
- The Gurobi Optimizer is utilized by the SAP® Integrated Business Planning for Supply Chain (SAP IBP) solution. SAP will look for new opportunities to embed the Gurobi Optimizer into other applications that benefit from mathematical optimization.
- Gurobi’s R&D department will commence a strategic cooperation with SAP, and will provide focused innovation support and consulting to SAP in all matters related to mathematical optimization.
“SAP and Gurobi share the same vision: to empower companies to benefit from mathematical optimization by using it to make optimal, data-driven decisions in this era of the Intelligent Enterprise. SAP and Gurobi will be working more closely together to spearhead greater innovation and adoption of mathematical optimization across SAP’s enterprise applications,” said Dr. Edward Rothberg, CEO of Gurobi Optimization.
About SAP
As the Experience Company powered by the Intelligent Enterprise, SAP is the market leader in enterprise application software, helping companies of all sizes and in all industries run at their best: 77% of the world’s transaction revenue touches an SAP system. Our machine learning, Internet of Things (IoT), and advanced analytics technologies help turn customers’ businesses into intelligent enterprises. SAP helps give people and organizations deep business insight and fosters collaboration that helps them stay ahead of their competition. We simplify technology for companies so they can consume our software the way they want – without disruption. Our end-to-end suite of applications and services enables more than 440,000 business and public customers to operate profitably, adapt continuously, and make a difference. With a global network of customers, partners, employees, and thought leaders, SAP helps the world run better and improve people’s lives. For more information, visit www.sap.com.
About Gurobi Optimization
Gurobi produces the world’s fastest and most powerful mathematical optimization solver – the Gurobi Optimizer – which is used by leading global companies across more than 40 different industries to rapidly solve their complex, real-world problems and make automated decisions that optimize their efficiency and profitability.
As the market leader in mathematical optimization software, we aim to deliver not only the best solver, but also the best support – so that companies can fully leverage the power of mathematical optimization (on its own or in combination with other AI techniques such as machine learning) to drive optimal business decisions and outcomes.
Founded in 2008, Gurobi has operations across the USA, Europe, and Asia and more than 2,400 customers globally including SAP, Air France, Uber, and the National Football League (NFL). For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005232/en/
Contact information
Isela Warner
Gurobi Optimization, LLC
775-771-2826
warner@gurobi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Launches AI Security Fabric, Providing AI Runtime Security for Agentic AI and LLM-Powered Applications11.12.2025 10:00:00 EET | Press release
AI is one of the fastest-growing technologies in the history of modern business, with the ability to revolutionize industries, optimize operations, and drive innovation, but it is also introducing security gaps, risks, and vulnerabilities. According to McKinsey, 78% of organizations are using AI in at least one business function, up from 55% two years ago. As a result, 73% of them are investing in AI-specific security tools, either with new or existing budgets, according to the 2025 Thales Data Threat Report. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211710650/en/ Thales AI Security Fabric Thales is introducing the first foundational capabilities of its AI Security Fabric to protect the core and edge of enterprises' AI ecosystems. Thales AI Security Fabric – Safeguarding LLM-Powered Apps, Data, and Identities With Thales AI Security Fabric, organizations will be able to: Unlock AI-driven growth securely: Maximize AI’
Interactive Brokers Adds Access to Brazil’s B3 Exchange11.12.2025 10:00:00 EET | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced that eligible clients outside of Brazil can now trade Brazilian equities through B3, the Brazil Stock Exchange. This expansion gives investors more ways to access emerging market opportunities across Latin America alongside global stocks, options, futures, currencies, bonds, funds, and more through a single unified platform. The B3 Exchange is one of the most active and liquid markets in the region. With this addition, investors will have direct access to trade Brazilian equities, plus over 160 markets worldwide using Interactive Brokers’ powerful trading platforms and tools. “Global investors need seamless access to diverse markets to stay competitive,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “By adding Brazil’s B3 Exchange, we’re giving our clients efficient, low-cost access to one of the world’s most dynamic emerging economies through our unified global platform.” Int
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman11.12.2025 09:30:00 EET | Press release
Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the Board of Directors’ decision to appoint Abdul Mullick, Ph.D., currently President and Chief Operating Officer (COO), to the role of President and Chief Executive Officer (CEO). The appointment will become effective March 2026 following the conclusion of the Ordinary General Meeting of Shareholders. As Mullick takes on the role of President and CEO for Kyowa Kirin, current CEO Masashi Miyamoto, Ph.D., remains Chairman. In March 2025, shareholders approved a dual CEO / COO model, with Mullick appointed to the newly created role of Chief Operating Officer, partnering with Miyamoto to lead the global organisation. The model provided a transition period for Mullick to gain greater insights and understanding of the Japanese company, as the first non-Japanese CEO in the company’s long history. By reverting to the single leader model under Mullick in 2026, Kyowa Kirin aims
Tosi solmi merkittävän sopimuksen johtavan midstream-yhtiön EPIC Cruden kanssa11.12.2025 09:07:00 EET | Tiedote
OT-kyberturvallisuusalustojen globaali johtaja Tosi vahvistaa toimintaansa Yhdysvalloissa, ja yhtiö on solminut merkittävän tilaussopimuksen raakaöljyn kuljetuspalveluja tarjoavan johtavan midstream-toimijan EPIC Cruden kanssa. Aiemmin tänä vuonna solmittu arvoltaan kuusinumeroinen tilaussopimus on Tosin historian suurin. Sopimus vahvistaa merkittävästi Tosin asemaa öljy- ja kaasuteollisuudessa. Sopimus kattaa OT-verkkoinfrastruktuurin kokonaisvaltaisen korvaamisen uudella ratkaisulla sekä jatkuvan ylläpidon EPIC Cruden laaja-alaisissa toiminnoissa. EPIC Crudella on eri puolilla Texasia putkistoa 800 mailin pituudelta yhdistäen Delawaren, Midlandin ja Eagle Fordin öljykentät Meksikonlahden markkinoihin. EPIC Crude valitsi liiketoimintansa muuttuessa Tosin toimittamaan nopean, skaalautuvan ja kustannustehokkaan ratkaisun yhtiön nykyisen kuitupohjaisen verkon tilalle. Ennen käyttöönottoa Tosin tiimi perehtyi konsultoivalla lähestymistavalla EPIC Cruden liiketoimintavaatimuksiin. Tältä po
Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin11.12.2025 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating patients living with Chronic Pruritus of Unknown Origin (CPUO). The first patient of the trial – which is taking place in the United States – was enrolled at Dr. Vlada Groysman’s site in Birmingham, Alabama. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210261871/en/ CPUO is an underdiagnosed condition defined as itch lasting for more than six weeks without an identified cause.1 It is a common condition and prevalent in nearly 30% of the elderly in certain populations, but despite its debilitating impact – with effects on sleep, mental health, and overall quality of life – there are currently no approved treatments.1,7 Nemolizumab is a monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom